MONTREAL, June 23, 2023 (GLOBE NEWSWIRE) — The Montreal Heart Institute (MHI) welcomes the approval by the United States Food and Drug Administration (FDA) of colchicine for cardiovascular prevention. Low-dose colchicine (0.5 mg once daily) is the first approved anti-inflammatory medication to reduce the risk of myocardial infarction (heart attack), stroke, coronary revascularization, and cardiovascular […]